LT2960238T - Monociklinis piridino darinys - Google Patents
Monociklinis piridino darinysInfo
- Publication number
- LT2960238T LT2960238T LTEP14754294.8T LT14754294T LT2960238T LT 2960238 T LT2960238 T LT 2960238T LT 14754294 T LT14754294 T LT 14754294T LT 2960238 T LT2960238 T LT 2960238T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyridine derivative
- monocyclic pyridine
- monocyclic
- derivative
- pyridine
- Prior art date
Links
- -1 Monocyclic pyridine derivative Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766922P | 2013-02-20 | 2013-02-20 | |
| PCT/JP2014/053819 WO2014129477A1 (ja) | 2013-02-20 | 2014-02-18 | 単環ピリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2960238T true LT2960238T (lt) | 2017-07-10 |
Family
ID=51351646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14754294.8T LT2960238T (lt) | 2013-02-20 | 2014-02-18 | Monociklinis piridino darinys |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8933099B2 (lt) |
| EP (1) | EP2960238B1 (lt) |
| JP (2) | JP5600229B1 (lt) |
| KR (1) | KR102050128B1 (lt) |
| CN (1) | CN105073730B (lt) |
| AR (1) | AR094812A1 (lt) |
| AU (1) | AU2014219811B2 (lt) |
| BR (1) | BR112015019790B1 (lt) |
| CA (1) | CA2901585C (lt) |
| CL (1) | CL2015002311A1 (lt) |
| CY (1) | CY1119220T1 (lt) |
| DK (1) | DK2960238T3 (lt) |
| ES (1) | ES2628495T3 (lt) |
| HK (1) | HK1215949A1 (lt) |
| HR (1) | HRP20170873T1 (lt) |
| HU (1) | HUE032931T2 (lt) |
| IL (1) | IL240623B (lt) |
| JO (1) | JO3261B1 (lt) |
| LT (1) | LT2960238T (lt) |
| ME (1) | ME02755B (lt) |
| MX (1) | MX361870B (lt) |
| MY (1) | MY178760A (lt) |
| NZ (1) | NZ711101A (lt) |
| PE (1) | PE20151509A1 (lt) |
| PH (1) | PH12015501813A1 (lt) |
| PL (1) | PL2960238T3 (lt) |
| PT (1) | PT2960238T (lt) |
| RS (1) | RS56064B1 (lt) |
| RU (1) | RU2645352C2 (lt) |
| SG (1) | SG11201506488WA (lt) |
| SI (1) | SI2960238T1 (lt) |
| SM (1) | SMT201700288T1 (lt) |
| TW (4) | TWI672296B (lt) |
| UA (1) | UA116794C2 (lt) |
| WO (1) | WO2014129477A1 (lt) |
| ZA (1) | ZA201505941B (lt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2956270C (en) * | 2014-08-18 | 2022-08-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
| JP6503450B2 (ja) * | 2015-03-25 | 2019-04-17 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| CN108367000A (zh) * | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| CN107098884A (zh) * | 2016-02-19 | 2017-08-29 | 中国科学院上海药物研究所 | 一类取代的氨基吡啶类化合物及其制备和用途 |
| JP2020536846A (ja) * | 2017-10-12 | 2020-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ選択的チロシンキナーゼ阻害剤を含む医薬組成物 |
| CA3091153A1 (en) | 2018-03-28 | 2019-10-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| MX2022012934A (es) | 2020-04-17 | 2022-11-08 | Eisai R&D Man Co Ltd | Agente terapeutico para cancer de mama. |
| CA3185174A1 (en) | 2020-07-31 | 2022-02-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| WO2022092085A1 (ja) | 2020-10-28 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP4361143A1 (en) | 2021-08-31 | 2024-05-01 | Eisai R&D Management Co., Ltd. | Method for producing monocyclic pyridine derivative |
| CN117677613A (zh) | 2021-08-31 | 2024-03-08 | 卫材R&D管理有限公司 | 单环吡啶衍生物的合成中间体的制造方法 |
| AU2023236231A1 (en) * | 2022-03-18 | 2024-09-05 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
| KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| WO2002081420A1 (fr) | 2001-04-03 | 2002-10-17 | Eisai Co., Ltd. | Derive de cyclooctanone et derive de cyclodecanone et utilisation de ces derives |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| AU2003261807B9 (en) | 2002-08-30 | 2007-02-15 | Eisai R & D Management Co., Ltd. | Azaarene derivatives |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| RU2350617C2 (ru) | 2003-04-10 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр |
| US20050256154A1 (en) | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| CN101218228A (zh) * | 2005-05-23 | 2008-07-09 | 诺瓦提斯公司 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式 |
| CA2634047C (en) | 2005-12-21 | 2016-04-12 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1891955A1 (en) | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| CA2672213C (en) | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
| EP2114941B1 (en) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US20100130796A1 (en) | 2007-06-25 | 2010-05-27 | Combes David J | Heater suitable for use in a preconcentrator device |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| WO2009056886A1 (en) | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Pyrimidine derivatives and their use as modulators of fgfr activity |
| WO2009076660A2 (en) * | 2007-12-13 | 2009-06-18 | Tyratech, Inc. | Organic absorbent material and uses thereof |
| CL2008003675A1 (es) * | 2007-12-13 | 2009-03-20 | Wyeth Corp | Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide. |
| GEP20125502B (en) | 2008-05-23 | 2012-04-25 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| EA201100030A1 (ru) | 2008-06-19 | 2011-08-30 | Астразенека Аб | Пиразольные соединения 436 |
| AU2009335019A1 (en) | 2008-12-30 | 2011-08-18 | Arqule, Inc. | Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| WO2010078421A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds |
| CA2748276A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted pyrazolo [3, 4-b] pyridine compounds |
| US9002427B2 (en) | 2009-03-30 | 2015-04-07 | Lifewave Biomedical, Inc. | Apparatus and method for continuous noninvasive measurement of respiratory function and events |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
| HUE028584T2 (en) | 2009-08-07 | 2016-12-28 | Chugai Pharmaceutical Co Ltd | Aminopyrazole derivatives |
| ES2524548T3 (es) | 2009-10-30 | 2014-12-10 | Novartis Ag | N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| ES2516392T3 (es) | 2012-01-19 | 2014-10-30 | Taiho Pharmaceutical Co., Ltd. | Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo |
| AR090161A1 (es) | 2012-02-28 | 2014-10-22 | Astellas Pharma Inc | Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| SMT202000673T1 (it) | 2012-06-13 | 2021-01-05 | Incyte Holdings Corp | Composti triciclici sostituiti come inibitori di fgfr |
| LT2872491T (lt) | 2012-07-11 | 2021-08-25 | Blueprint Medicines Corporation | Fibroblasto augimo faktoriaus receptoriaus inhibitoriai |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| WO2014048878A1 (en) | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
| EA031631B1 (ru) | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
| TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
-
2014
- 2014-02-17 AR ARP140100495A patent/AR094812A1/es active IP Right Grant
- 2014-02-18 HU HUE14754294A patent/HUE032931T2/en unknown
- 2014-02-18 TW TW107134522A patent/TWI672296B/zh active
- 2014-02-18 SI SI201430247A patent/SI2960238T1/sl unknown
- 2014-02-18 PE PE2015001748A patent/PE20151509A1/es active IP Right Grant
- 2014-02-18 MX MX2015010698A patent/MX361870B/es active IP Right Grant
- 2014-02-18 AU AU2014219811A patent/AU2014219811B2/en active Active
- 2014-02-18 JP JP2014526292A patent/JP5600229B1/ja active Active
- 2014-02-18 CN CN201480009370.XA patent/CN105073730B/zh active Active
- 2014-02-18 TW TW107134529A patent/TWI672140B/zh active
- 2014-02-18 PT PT147542948T patent/PT2960238T/pt unknown
- 2014-02-18 CA CA2901585A patent/CA2901585C/en active Active
- 2014-02-18 UA UAA201508149A patent/UA116794C2/uk unknown
- 2014-02-18 RU RU2015134558A patent/RU2645352C2/ru active
- 2014-02-18 TW TW103105419A patent/TWI641602B/zh active
- 2014-02-18 PL PL14754294T patent/PL2960238T3/pl unknown
- 2014-02-18 SG SG11201506488WA patent/SG11201506488WA/en unknown
- 2014-02-18 ES ES14754294.8T patent/ES2628495T3/es active Active
- 2014-02-18 ME MEP-2017-130A patent/ME02755B/me unknown
- 2014-02-18 WO PCT/JP2014/053819 patent/WO2014129477A1/ja active Application Filing
- 2014-02-18 JO JOP/2014/0039A patent/JO3261B1/ar active
- 2014-02-18 MY MYPI2015702696A patent/MY178760A/en unknown
- 2014-02-18 TW TW107134526A patent/TWI672139B/zh active
- 2014-02-18 SM SM20170288T patent/SMT201700288T1/it unknown
- 2014-02-18 BR BR112015019790-6A patent/BR112015019790B1/pt active IP Right Grant
- 2014-02-18 NZ NZ711101A patent/NZ711101A/en unknown
- 2014-02-18 KR KR1020157022252A patent/KR102050128B1/ko active IP Right Grant
- 2014-02-18 RS RS20170596A patent/RS56064B1/sr unknown
- 2014-02-18 LT LTEP14754294.8T patent/LT2960238T/lt unknown
- 2014-02-18 DK DK14754294.8T patent/DK2960238T3/en active
- 2014-02-18 EP EP14754294.8A patent/EP2960238B1/en active Active
- 2014-02-19 US US14/183,864 patent/US8933099B2/en active Active
- 2014-08-14 JP JP2014165311A patent/JP2014237707A/ja active Pending
-
2015
- 2015-08-17 IL IL240623A patent/IL240623B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05941A patent/ZA201505941B/en unknown
- 2015-08-18 CL CL2015002311A patent/CL2015002311A1/es unknown
- 2015-08-18 PH PH12015501813A patent/PH12015501813A1/en unknown
-
2016
- 2016-04-06 HK HK16103911.2A patent/HK1215949A1/zh unknown
-
2017
- 2017-06-07 HR HRP20170873TT patent/HRP20170873T1/hr unknown
- 2017-06-15 CY CY20171100631T patent/CY1119220T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215949A1 (zh) | 單環吡啶衍生物 | |
| HK1215795A1 (zh) | 鵝膏毒素衍生物 | |
| LT2953944T (lt) | Piridazinono amidų dariniai | |
| HK1211938A1 (en) | Novel pyridine derivatives | |
| HK1220454A1 (zh) | 吡啶- -基衍生物 | |
| PL3027598T3 (pl) | Pochodne oksochinazolinylo-butanoamidowe | |
| HK1220200A1 (zh) | 乙炔基衍生物 | |
| PL3087076T3 (pl) | Pochodne imidazopirazynonowe | |
| EP3009444A4 (en) | ALPHA-oxoacyl-Amino-caprolactam derivative |